ATE482969T1 - 3-beta-hydroxy-17-(1h-benzimidazol-1-yl)androst - 5,16-dien zur anwendung in der behandlung von prostata-erkrankungen - Google Patents
3-beta-hydroxy-17-(1h-benzimidazol-1-yl)androst - 5,16-dien zur anwendung in der behandlung von prostata-erkrankungenInfo
- Publication number
- ATE482969T1 ATE482969T1 AT06736460T AT06736460T ATE482969T1 AT E482969 T1 ATE482969 T1 AT E482969T1 AT 06736460 T AT06736460 T AT 06736460T AT 06736460 T AT06736460 T AT 06736460T AT E482969 T1 ATE482969 T1 AT E482969T1
- Authority
- AT
- Austria
- Prior art keywords
- diene
- treatment
- methods
- androst
- benzimidazole
- Prior art date
Links
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 210000002307 prostate Anatomy 0.000 title 1
- 238000000034 method Methods 0.000 abstract 3
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical class C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 abstract 2
- KCTZOTUQSGYWLV-UHFFFAOYSA-N N1C=NC=C2N=CC=C21 Chemical class N1C=NC=C2N=CC=C21 KCTZOTUQSGYWLV-UHFFFAOYSA-N 0.000 abstract 2
- 102000001307 androgen receptors Human genes 0.000 abstract 2
- 108010080146 androgen receptors Proteins 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 230000003389 potentiating effect Effects 0.000 abstract 2
- 102000004190 Enzymes Human genes 0.000 abstract 1
- 108090000790 Enzymes Proteins 0.000 abstract 1
- 101100298362 Homo sapiens PPIG gene Proteins 0.000 abstract 1
- 206010060862 Prostate cancer Diseases 0.000 abstract 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 abstract 1
- 239000005557 antagonist Substances 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 150000004891 diazines Chemical class 0.000 abstract 1
- 238000003379 elimination reaction Methods 0.000 abstract 1
- 102000056262 human PPIG Human genes 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 239000012038 nucleophile Substances 0.000 abstract 1
- 230000000269 nucleophilic effect Effects 0.000 abstract 1
- 238000010651 palladium-catalyzed cross coupling reaction Methods 0.000 abstract 1
- 230000003637 steroidlike Effects 0.000 abstract 1
- 238000006467 substitution reaction Methods 0.000 abstract 1
- 238000003786 synthesis reaction Methods 0.000 abstract 1
- DBHSVKZZSWTSTN-UHFFFAOYSA-N tributyl(pyridazin-3-yl)stannane Chemical class CCCC[Sn](CCCC)(CCCC)C1=CC=CN=N1 DBHSVKZZSWTSTN-UHFFFAOYSA-N 0.000 abstract 1
- 125000002348 vinylic group Chemical group 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
- C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US65739005P | 2005-03-02 | 2005-03-02 | |
| PCT/US2006/007143 WO2006093993A1 (en) | 2005-03-02 | 2006-03-02 | Novel c-17-heteroaryl steroidal cyp17 inhibitors/antiandrogens: synthesis, in vitro biological activities, pharmacokinetics and antitumor activity |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE482969T1 true ATE482969T1 (de) | 2010-10-15 |
Family
ID=36941503
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT06736460T ATE482969T1 (de) | 2005-03-02 | 2006-03-02 | 3-beta-hydroxy-17-(1h-benzimidazol-1-yl)androst - 5,16-dien zur anwendung in der behandlung von prostata-erkrankungen |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US7875599B2 (enExample) |
| EP (2) | EP2206719B1 (enExample) |
| JP (2) | JP5130453B2 (enExample) |
| KR (1) | KR101380959B1 (enExample) |
| CN (2) | CN101155823A (enExample) |
| AT (1) | ATE482969T1 (enExample) |
| AU (1) | AU2006218711B2 (enExample) |
| BR (1) | BRPI0607523A2 (enExample) |
| CA (1) | CA2599953C (enExample) |
| DE (1) | DE602006017175D1 (enExample) |
| DK (2) | DK2206719T3 (enExample) |
| EA (1) | EA019560B1 (enExample) |
| ES (2) | ES2528055T3 (enExample) |
| IL (3) | IL185608A (enExample) |
| MX (1) | MX2007010593A (enExample) |
| NZ (1) | NZ561571A (enExample) |
| PL (2) | PL2206719T3 (enExample) |
| PT (2) | PT1853619E (enExample) |
| SI (2) | SI2206719T1 (enExample) |
| WO (1) | WO2006093993A1 (enExample) |
| ZA (1) | ZA200708106B (enExample) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8569275B2 (en) | 2002-08-28 | 2013-10-29 | Harbor Therapeutics, Inc. | Steroids having 7-oxgen and 17-heteroaryl substitution |
| ATE482969T1 (de) * | 2005-03-02 | 2010-10-15 | Univ Maryland | 3-beta-hydroxy-17-(1h-benzimidazol-1-yl)androst - 5,16-dien zur anwendung in der behandlung von prostata-erkrankungen |
| GB2454118B (en) | 2007-06-06 | 2010-06-02 | Univ Maryland | Hdac inhibitors and hormone targeted drugs for the treatment of cancer |
| GB2470873A (en) * | 2008-03-12 | 2010-12-08 | Univ Maryland | Androgen receptor inactivation contributes to antitumor efficacy of CYP17 inhibitors in prostrate cancer |
| US20100048913A1 (en) * | 2008-03-14 | 2010-02-25 | Angela Brodie | Novel C-17-Heteroaryl Steroidal CYP17 Inhibitors/Antiandrogens;Synthesis In Vitro Biological Activities, Pharmacokinetics and Antitumor Activity |
| GB2470700B (en) * | 2008-03-25 | 2012-08-08 | Univ Maryland | C-17 heteroaryl steroidal CYP17 inhibitors |
| US8785423B2 (en) * | 2008-04-14 | 2014-07-22 | University Of Maryland, Baltimore | Compositions and methods of inducing endoplasmic reticulum stress response for the treatment of cell proliferative diseases |
| US20110190323A1 (en) | 2008-08-28 | 2011-08-04 | President And Fellows Of Harvard College | Cortistatin analogues and syntheses thereof |
| CN102282133A (zh) * | 2008-10-28 | 2011-12-14 | 生物马林药物股份有限公司 | 十氢-1h-茚并喹啉酮和十氢-3h-环戊并菲啶酮cyp17抑制剂 |
| GB2479337A (en) * | 2009-02-05 | 2011-10-05 | Tokai Pharmaceuticals Inc | Combination of a 17 alpha-hydroxylase/c17, 20-lyase inhibitor with an additional therapeutic agent |
| US8791095B2 (en) | 2009-02-05 | 2014-07-29 | Tokai Pharmaceuticals, Inc. | Steroidal CYP17 inhibitors/antiandrogens |
| US20110312916A1 (en) * | 2009-02-05 | 2011-12-22 | Tokai Pharmaceuticals, Inc. | Novel prodrugs of steroidal cyp17 inhibitors/antiandrogens |
| SG176105A1 (en) | 2009-06-26 | 2011-12-29 | Novartis Ag | 1, 3-disubstituted imidazolidin-2-one derivatives as inhibitors of cyp 17 |
| US8791094B2 (en) * | 2009-08-07 | 2014-07-29 | Tokai Pharmaceuticals, Inc. | Treatment of prostate cancer |
| BR112012012167A2 (pt) * | 2009-11-13 | 2017-10-03 | Tokai Pharmaceuticals Inc | Metabólitos mamíferos de esteróides |
| US20110129423A1 (en) * | 2009-11-30 | 2011-06-02 | Frincke James M | Anticancer compounds and screening method |
| CN103108871B (zh) | 2010-09-16 | 2014-09-10 | 诺华股份有限公司 | 17α-羟化酶/C17,20-裂合酶抑制剂 |
| RU2013132766A (ru) * | 2010-12-16 | 2015-01-27 | Байомарин Фармасьютикал Инк. | Ингибиторы cyp11b, cyp17 и/или cyp21 |
| US9029399B2 (en) | 2011-04-28 | 2015-05-12 | Novartis Ag | 17α-hydroxylase/C17,20-lyase inhibitors |
| JP2014523445A (ja) * | 2011-07-18 | 2014-09-11 | トーカイ ファーマシューティカルズ，インク． | 前立腺癌を処置するための新規な組成物及び方法 |
| WO2013096907A1 (en) * | 2011-12-22 | 2013-06-27 | Tokai Pharmaceuticals, Inc. | Methods and compositions for combination therapy using p13k/mtor inhibitors |
| KR20150127720A (ko) | 2013-03-14 | 2015-11-17 | 유니버시티 오브 매릴랜드, 발티모어 | 안드로겐 수용체 하향 조절제 및 그의 용도 |
| EP3514147B1 (en) * | 2013-04-04 | 2022-08-03 | University of Maryland, Baltimore | Steroidal compounds with potent androgen receptor down-regulation and anti prostate cancer activity |
| EP3033088A4 (en) | 2013-08-12 | 2017-03-08 | Tokai Pharmaceuticals, Inc. | Biomarkers for treatment of neoplastic disorders using androgen-targeted therapies |
| AU2014369834B2 (en) | 2013-12-24 | 2018-12-20 | President And Fellows Of Harvard College | Cortistatin analogues and syntheses and uses thereof |
| CN103694299A (zh) * | 2014-01-13 | 2014-04-02 | 中国药科大学 | 甾体类雄激素受体抑制剂、其制备方法及其医药用途 |
| CN105732759A (zh) * | 2015-01-29 | 2016-07-06 | 苏州晶云药物科技有限公司 | (3β)-17-(1H-苯并咪唑-1-基)雄甾-5，16-二烯-3-醇的盐及其制备方法 |
| WO2016182932A1 (en) | 2015-05-08 | 2016-11-17 | President And Fellows Of Harvard College | Cortistatin analogues, syntheses, and uses thereof |
| EP3316889A4 (en) | 2015-07-01 | 2018-11-14 | President and Fellows of Harvard College | Cortistatin analogues and syntheses and uses thereof |
| WO2017066697A1 (en) | 2015-10-14 | 2017-04-20 | Dou Qingping | Treatments and diagnostics for cancers |
| IT201600121375A1 (it) * | 2016-11-30 | 2018-05-30 | Ind Chimica Srl | PROCESSO PER LA PREPARAZIONE DI 3ß-IDROSSI-17-(1H-BENZIMIDAZOL-1-IL)ANDROSTA-5,16-DIENE |
| RU2749134C1 (ru) * | 2016-08-08 | 2021-06-04 | Индустриале Кимика С.Р.Л. | СПОСОБ ПОЛУЧЕНИЯ 3β-ГИДРОКСИ-17-(1Н-БЕНЗИМИДАЗОЛ-1-ИЛ)АНДРОСТА-5,16-ДИЕНА |
| IT201600083406A1 (it) * | 2016-08-08 | 2018-02-08 | Ind Chimica Srl | PROCESSO PER LA PREPARAZIONE DI 3β-IDROSSI-17-(1H-BENZIMIDAZOL-1-IL)ANDROSTA-5,16-DIENE |
| CA3087286C (en) | 2018-02-13 | 2023-06-27 | Dana-Farber Cancer Institute, Inc. | Cyclin-dependent kinase degraders and methods of use |
| EP3752518B1 (en) * | 2018-02-13 | 2024-12-04 | Dana-Farber Cancer Institute, Inc. | Cyclin-dependent kinase inhibitors and methods of use |
| WO2021108581A1 (en) | 2019-11-26 | 2021-06-03 | Dana-Farber Cancer Institute, Inc. | Potent and selective azaindole inhibitors of cdk8 and cdk19 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA27440A (en) | 1887-08-16 | James T. Walsh | Art of making sheet metal cans, for packing meats, fruits, vegetables, etc. | |
| CH621803A5 (enExample) * | 1974-08-08 | 1981-02-27 | Siphar Sa | |
| US5604213A (en) * | 1992-03-31 | 1997-02-18 | British Technology Group Limited | 17-substituted steroids useful in cancer treatment |
| US5994335A (en) | 1997-10-17 | 1999-11-30 | The University Of Maryland, Baltimore | 17-azolyl steroids useful as androgen synthesis inhibitors |
| WO2005014023A1 (en) | 2003-07-29 | 2005-02-17 | Dompe' Pha.R.Ma S.P.A. | Pharmaceutical combination of g-csf and plgf useful for blood stem cell |
| ATE482969T1 (de) * | 2005-03-02 | 2010-10-15 | Univ Maryland | 3-beta-hydroxy-17-(1h-benzimidazol-1-yl)androst - 5,16-dien zur anwendung in der behandlung von prostata-erkrankungen |
-
2006
- 2006-03-02 AT AT06736460T patent/ATE482969T1/de active
- 2006-03-02 CN CNA2006800064632A patent/CN101155823A/zh active Pending
- 2006-03-02 SI SI200631883T patent/SI2206719T1/sl unknown
- 2006-03-02 EP EP10150763.0A patent/EP2206719B1/en active Active
- 2006-03-02 ES ES10150763.0T patent/ES2528055T3/es active Active
- 2006-03-02 EP EP06736460A patent/EP1853619B1/en active Active
- 2006-03-02 CA CA2599953A patent/CA2599953C/en active Active
- 2006-03-02 ES ES06736460T patent/ES2353413T3/es active Active
- 2006-03-02 AU AU2006218711A patent/AU2006218711B2/en active Active
- 2006-03-02 US US11/817,550 patent/US7875599B2/en active Active
- 2006-03-02 SI SI200630861T patent/SI1853619T1/sl unknown
- 2006-03-02 DK DK10150763.0T patent/DK2206719T3/en active
- 2006-03-02 JP JP2007558143A patent/JP5130453B2/ja active Active
- 2006-03-02 DK DK06736460.4T patent/DK1853619T3/da active
- 2006-03-02 NZ NZ561571A patent/NZ561571A/en not_active IP Right Cessation
- 2006-03-02 MX MX2007010593A patent/MX2007010593A/es active IP Right Grant
- 2006-03-02 EA EA200701872A patent/EA019560B1/ru not_active IP Right Cessation
- 2006-03-02 CN CN2013101036754A patent/CN103349664A/zh active Pending
- 2006-03-02 WO PCT/US2006/007143 patent/WO2006093993A1/en not_active Ceased
- 2006-03-02 PT PT06736460T patent/PT1853619E/pt unknown
- 2006-03-02 PT PT101507630T patent/PT2206719E/pt unknown
- 2006-03-02 BR BRPI0607523-1A patent/BRPI0607523A2/pt not_active IP Right Cessation
- 2006-03-02 KR KR1020077022440A patent/KR101380959B1/ko not_active Expired - Fee Related
- 2006-03-02 PL PL10150763T patent/PL2206719T3/pl unknown
- 2006-03-02 PL PL06736460T patent/PL1853619T3/pl unknown
- 2006-03-02 DE DE602006017175T patent/DE602006017175D1/de active Active
-
2007
- 2007-08-30 IL IL185608A patent/IL185608A/en not_active IP Right Cessation
- 2007-09-20 ZA ZA200708106A patent/ZA200708106B/xx unknown
-
2011
- 2011-01-06 IL IL210480A patent/IL210480A/en not_active IP Right Cessation
- 2011-01-06 IL IL210478A patent/IL210478A0/en unknown
-
2012
- 2012-09-06 JP JP2012196525A patent/JP5613206B2/ja active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE482969T1 (de) | 3-beta-hydroxy-17-(1h-benzimidazol-1-yl)androst - 5,16-dien zur anwendung in der behandlung von prostata-erkrankungen | |
| NO2017019I2 (no) | Enzalutamid eller et farmasøytisk akseptabelt salt derav | |
| PT1353672E (pt) | Síntese da 4-amino talidomida enantiómeros | |
| GEP20084551B (en) | 4-phenylamino-quinazolin-6-yl-amides | |
| WO2005013892A3 (en) | Hydrolytically-resistant boron-containing therapeutics and methods of use | |
| EA200900202A1 (ru) | Селективные модуляторы андрогенного рецептора, их аналоги и производные и их использование | |
| ATE450251T1 (de) | Liposomale formulierungen mit dihydrosphingomyelin und verfahren zu ihrer verwendung | |
| EP1805156A4 (en) | PREPARATION AND USE OF BIPHENYL-4-YL-CARBONYLAMINO-ACID DERIVATIVES FOR THE TREATMENT OF OBESITAS | |
| NO20083002L (no) | Fremgangsmate for anvendelse av CD40-bindende forbindelser | |
| IL195256A0 (en) | Compositions of r(+)and s(-)pramipexole and methods of using the same | |
| ZA200705115B (en) | Indazole-carboxamide compounds | |
| MX2007000606A (es) | Arilidenos para el tratamiento de enfermedades mediadas por receptor alfa relacionado con estrogeno. | |
| MXPA06009475A (es) | Derivados de quinazolina y usos terapeuticos de los mismos. | |
| SG152237A1 (en) | Pharmaceutical combinations containing benzoxazine for treating respiratory diseases | |
| UA96277C2 (en) | Benzimidazole derivatives | |
| MXPA05011699A (es) | Inhibidores de la bomba de protones para el tratamiento de trastornos del abdomen inferior. | |
| WO2007048097A3 (en) | Anbrosteeone derivatives and method of use thereof | |
| UA95780C2 (en) | Xanthine derivatives as selective hm74a agonists | |
| NO20060655L (no) | 2-alkyliden-19-Nor-vitamin D derivater for behandling av osteofeni eller osteoporose hos hannkjonn | |
| WO2007048034A3 (en) | Use of androgens for the treatment of parkinson' s disease | |
| WO2007045060A8 (en) | Pharmaceutical compositions containing erythrine mulungu derivatives and processes for their production | |
| CY1115910T1 (el) | ΦΑΡΜΑΚΕΥΤΙΚΗ ΣΥΝΘΕΣΗ ΠΟΥ ΠΕΡΙΛΑΜΒΑΝΕΙ 3-BETA-HYDROXY-17-(l-HBENZIMIDAZOLE-1-YL)ANDROSΤΑ-5,16-DIENE | |
| PL1732574T3 (pl) | Zastosowanie o-ATP do leczenia chorób związanych z angiogenezą | |
| TW200504044A (en) | Methods for preparing derivatives of fungicidal iodochromones and intermediate compounds | |
| TW200603812A (en) | D-homo-17-chlor-16(17)-ene steroids |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1853619 Country of ref document: EP |
|
| EEFA | Change of the company name |